āshibio is developing novel therapies for patients with rare bone and connective tissue disorders that have the potential to slow the progression of disease.
Investors 2
Mentions in press and media 2
| Date | Title | Description |
| 20.06.2024 | āshibio Raises $40M in Seed and Series A Financing | āshibio, a Brisbane, CA-based biotechnology company, raised $40M in Seed and Series A funding.
Backers of the Seed funding were not disclosed. MPM BioImpact led the Series A round, with contributing funds from Agent Capital, YK Bioventures,... |
| - | āshibio | “āshibio is developing novel therapies for patients with rare bone and connective tissue disorders that have the potential to prevent the onset of symptoms or slow the progression of disease.” |
Reviews 0
